Insider Transactions in Q1 2024 at Intra Cellular Therapies, Inc. (ITCI)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 17
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
48,084
-2.21%
|
$3,173,544
$66.33 P/Share
|
|
Jan 17
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
48,084
+4.19%
|
$769,344
$16.86 P/Share
|
|
Jan 16
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
75,361
-2.25%
|
$5,049,187
$67.13 P/Share
|
|
Jan 16
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
75,361
+6.27%
|
$1,205,776
$16.86 P/Share
|
|
Jan 11
2024
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
50,000
-77.21%
|
$3,350,000
$67.07 P/Share
|
|
Jan 11
2024
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+28.6%
|
$900,000
$18.34 P/Share
|
|
Jan 02
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
62,282
-83.73%
|
$4,359,740
$70.99 P/Share
|
|
Jan 02
2024
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,282
+50.0%
|
$1,183,358
$19.87 P/Share
|